Action on Antimicrobial Resistance

Antimicrobial resistance (AMR), often termed the "silent pandemic", is exacerbated by market failures in the development of new antibiotics and is projected to cost the global economy up to $100 trillion by 2050. This crisis is driven by insufficient incentives for the pharmaceutical industry, from low sales volumes to uncertain returns on investment. How can innovative financing models be leveraged to close this gap and preserve life-saving medicines? This session will be accompanied by the AMR Davos Declaration and the launch of a Unified Coalition for the AMR Response (UCARES), focusing on sustainable financing for antibiotics.